home / stock / incy / incy articles

INCY Articles, Incyte Corporation

Stock Information
Company Name: Incyte Corporation
Stock Symbol: INCY
Market: NASDAQ
Website: incyte.com
Menu
INCY INCY Quote INCY Short INCY News INCY Articles INCY Message Board
Get INCY Alerts

News, Short Squeeze, Breakout and More Instantly...
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday | Benzinga

U.S. stocks were higher, with the Dow Jones gaining more than 90 points on Monday. Shares of GameStop Corp. (NYSE:GME) rose sharply during Monday&#...
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends | Benzinga

Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million. Escient’s pipe...

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B | Benzinga

Monday, Novartis AG (NYSE:NVS) made a voluntary public takeover offer to acquire MorphoSys AG (NASDAQ:MOR) for ?...

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer | Benzinga

MorphoSys AG (NASDAQ:MOR) shares are trading higher Monday following a report suggesting Novartis AG (NYSE:NVS) is in talks to acquire the company....
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations | Benzinga

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topic...

What's Up With Incyte Stock Lately? | Benzinga

Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday. Here's what has happened. Wha...

S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets | Benzinga

The S&P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap from the all-time ...
Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness | Benzinga

Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management a...

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison | Benzinga

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary m...

Next 10